Treatment of Primary Ovarian Lymphoma in Splenic Marginal Zone Lymphoma

Primary ovarian lymphoma presenting in the context of splenic marginal zone lymphoma (SMZL) represents a distinct clinical situation requiring a tailored therapeutic approach. The management strategy is guided by the underlying SMZL and the patient's individual disease characteristics.

This protocol applies to patients diagnosed with primary ovarian lymphoma in whom splenic marginal zone lymphoma is the established or concurrent underlying lymphoma subtype. The specific features of SMZL — including disease extent, associated viral status, and response to prior interventions — directly shape the choice of management.

For most patients with SMZL in this setting, the initial treatment approach centres on a targeted monoclonal antibody therapy. In selected patients, additional strategies addressing underlying aetiology may also apply. The full decision algorithm — including criteria for escalation and alternative approaches when initial therapy is not suitable or is ineffective — is available in the complete protocol.